| Predicate |
Object |
| contentType |
Journal Article |
| endingPage |
732 |
| issn |
1178-203X |
| issueIdentifier |
4 |
| pageRange |
727-732 |
| publicationName |
Therapeutics and Clinical Risk Management |
| startingPage |
727 |
| bibliographicCitation |
Weide R. Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin's lymphoma. Ther Clin Risk Manag. 2008 Aug;4(4):727–32. PMID: 19209254; PMCID: PMC2621381. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3a898b1ba0e8a3902b7e9f50ae3b984a |
| date |
200808 |
| identifier |
https://doi.org/10.2147/tcrm.s3158
https://pubmed.ncbi.nlm.nih.gov/19209254
https://pubmed.ncbi.nlm.nih.gov/PMC2621381 |
| isPartOf |
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/33049
https://portal.issn.org/resource/ISSN/1178-203X |
| language |
English |
| source |
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10603
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65628
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7947
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1044
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8390
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8388
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6847
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4212
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID77082 |